Epilepsy | Disease Landscape & Forecast | G7 | 2021

Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on the patient’s seizure syndrome and seizure type. The epilepsy therapy market already comprises more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients. In this challenging market environment, developers increasingly target underserved, niche segments or subpopulations (e.g., orphan pediatric syndromes, rescue therapy) as a path to differentiation. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.

Questions Answered:

  • What is the current state of treatment in epilepsy in the G7, and what needs are left unfulfilled by approved AEDs?
  • What are the market opportunities for, and sales potential of, agents targeting treatment-refractory focal epilepsy (e.g., Xcopri) and agents targeting orphan epilepsy subpopulations (e.g., Epidiolex, Fintepla)?
  • What clinical role will recently approved and emerging acute rescue therapies (e.g., Nayzilam, Valtoco, Libervant) play in the epilepsy market?
  • How will neurologists differentiate between current and emerging third-generation AEDs, and which of these agents will experience the most clinical and commercial success in the face of strong generics competition from first- and second-generation AEDs?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 29 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.

Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.

Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase II products.

Market forecast features: Patient-based market forecast extending through 2030, segmented by brands/generics.

Key companies: Aquestive Therapeutics, Bial, Eisai, Eton Pharmaceuticals, Azurity Pharmaceuticals, GW Pharmaceuticals, Lundbeck, Marinus Pharmaceuticals, Neurelis, Sanofi, SK Biopharmaceuticals, UCB, Sunovion, Zogenix.

Key drugs: Levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), Epidiolex / Epidyolex (cannabidiol), Fintepla (fenfluramine), Xcopri / Onztory (cenobamate), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).

Solution Enhancement:

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Login to access report